Treatment of triple transgenic APP/PS1/tau (3×Tg-AD) mice with dexamethasone, a glucocorticoid receptor agonist, increases brain Aβ levels (Green et al., 2006). The gene discussed is MAPT; the disease is Alzheimer disease.